These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22132120)

  • 1. Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo.
    Kijima M; Gardiol N; Held W
    PLoS One; 2011; 6(11):e27639. PubMed ID: 22132120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
    Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
    Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.
    Sconocchia G; Lau M; Provenzano M; Rezvani K; Wongsena W; Fujiwara H; Hensel N; Melenhorst J; Li J; Ferrone S; Barrett AJ
    Blood; 2005 Nov; 106(10):3666-72. PubMed ID: 16046526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.
    Chen CI; Koschmieder S; Kerstiens L; Schemionek M; Altvater B; Pscherer S; Gerss J; Maecker HT; Berdel WE; Juergens H; Lee PP; Rossig C
    Leukemia; 2012 Mar; 26(3):465-74. PubMed ID: 21904381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
    Terme M; Borg C; Guilhot F; Masurier C; Flament C; Wagner EF; Caillat-Zucman S; Bernheim A; Turhan AG; Caignard A; Zitvogel L
    Cancer Res; 2005 Jul; 65(14):6409-17. PubMed ID: 16024645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophages protect mycoplasma-infected chronic myeloid leukemia cells from natural killer cell killing.
    Choo QWW; Koean RAG; Chang SC; Chng WJ; Chan MC; Wang W; Er JZ; Ding JL
    Immunol Cell Biol; 2020 Feb; 98(2):138-151. PubMed ID: 31837284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review).
    Lee HR; Baek KH
    Oncol Rep; 2019 May; 41(5):2625-2635. PubMed ID: 30896812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cancer immunology in chronic myelogenous leukemia.
    Ureshino H; Shindo T; Kimura S
    Leuk Res; 2020 Jan; 88():106273. PubMed ID: 31765938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of natural killer cells in the treatment of chronic myeloid leukemia.
    Silla LM; Whiteside TL; Ball ED
    J Hematother; 1995 Aug; 4(4):269-79. PubMed ID: 7489141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.
    Carlsten M; Järås M
    Front Immunol; 2019; 10():2357. PubMed ID: 31681270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
    Boissel N; Rea D; Tieng V; Dulphy N; Brun M; Cayuela JM; Rousselot P; Tamouza R; Le Bouteiller P; Mahon FX; Steinle A; Charron D; Dombret H; Toubert A
    J Immunol; 2006 Apr; 176(8):5108-16. PubMed ID: 16585609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic myeloid leukemia and NK cell immunity].
    Ureshino H; Shindo T; Tanaka H; Kimura S
    Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation.
    Cebo C; Da Rocha S; Wittnebel S; Turhan AG; Abdelali J; Caillat-Zucman S; Bourhis JH; Chouaib S; Caignard A
    J Immunol; 2006 Jan; 176(2):864-72. PubMed ID: 16393970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
    Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
    Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
    Pierson BA; Miller JS
    Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [NK cells: a major role in the antitumoral immunomodulation in CML].
    Toubert A; Turhan A; Guerci-Bresler A; Dulphy N; Réa D
    Med Sci (Paris); 2018; 34(6-7):540-546. PubMed ID: 30067206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.
    Hauch M; Gazzola MV; Small T; Bordignon C; Barnett L; Cunningham I; Castro-Malaspinia H; O'Reilly RJ; Keever CA
    Blood; 1990 Jun; 75(11):2250-62. PubMed ID: 2189508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.
    Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H
    Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.